Bart De Spiegeleer

1. Quality and analytics of medicines for discovery, preclinical investigations, clinical trials and post-approvals (EU recognized GMP-laboratory; EMA quality expert).
2. Regulatory affairs of health products, with emphasis on medicines, over their life cycle, from discovery to market access.
3. ADME in rodents (incl. BBB study) and transdermal/mucosal diffusion experiments (Franz cells using human skin and porcine oral mucosa).
4. Peptides as bioactive molecules (biomarkers, medicines): (bio)analytics, target interaction, pharmacodynamics and pharmacokinetics (receptor, cell, tissue/organ, rodent). A special peptide focus is on the quorum sensing peptides, produced by micro-organisms including our microbiome. This group of bacterial molecules is also an explanatory factor in the host-microbiome interaction (e.g. cancer, psychiatric diseases, immune system, sarcopenia).

Prof. Dr. De Spiegeleer received a Master degree in Pharmaceutical Sciences (1982) and a second degree in Teaching Education (1986) from Ghent University. He was a research fellow at the University of Manchester (UK) (1988). He also completed his Doctoral Degree in Pharmaceutical Sciences at Ghent University (1989) on anticancer platinum compounds. He followed postgraduate business administration (KUL, 1988) and middle management programme at the Vlerick’s Management School (1993). Being an industrial pharmacist (1986), he is a registered qualified person for the release of pharmaceutical products as well as a responsible person for pharmaco-vigilance (2000) and pharmaceutical information (2000).

Previously, Prof. Dr. De Spiegeleer worked in the pharmaceutical industry as qualified person, QA-QC head, regulatory affairs, technical and R&D manager at Federa and Couvreur (1989-1994). He was the founder and general manager of several small and medium enterprises (1994-2008) such as HEA (now Ardena), IDPhar, Chemiphar, Anabiotec, Phuso (now Bouteligier & De Kerf). From 2004-2008, he was part-time guest-professor at Ghent University, and since October 2008 full-time professor.

Prof. Dr. De Spiegeleer’s work has appeared in numerous publications, meeting-abstracts and patents, including peer reviewed journals like Analytical Chemistry, Nature Materials, Talanta, Analytical Chimica Acta, Journal of Nuclear Medicine, Journal of Pharmaceutical and Biomedical Analysis, Journal of Chromatography. He was one of the founders and Editor of Journal of Planar Chromatography (1988-1991). He currently serves as editor (e.g. Journal of Pharmaceutical Analysis) and referee for different international scientific journals.

Prof. Dr. De Spiegeleer also teaches Advanced Drug Analysis and Quality, Regulatory Affairs of Health Products, Pharmaceutical management skills, Regulatory Quality of medicines, Pharmaceutical-Industrial Regulatory Affairs and the Integrated Bachelor Course. He is the principal coordinator of the Erasmus+ Mundus Joint Master Degree Programme in Sustainable Drug Discovery (acronym: S-DISCO). This EU partnership of four universities and more than 20 associated academic and industrial partners was selected in 2021 by the European Commission to provide funding for talented students from all over the world. He is an EMA expert, member of the Belgian Pharmacopoeial Commission, as well as of the Commission on the elaboration of technical monographs for pharmaceutical ingredients.